A&P, 4D team up through Live Better! program
MONTVALE, N.J. A&P announced on Thursday that it has teamed up with 4D Pharmacy Management Systems to administer employer group prescription drug benefits through its Live Better! Wellness Program.
Under the agreement, employer groups will have access to 4D’s nationwide network of more than 60,000 pharmacies as well as incentives at the company’s participating banner store Pharmacy Centers. The Live Better! Wellness Program begins managing pharmacy benefits Jan. 1, 2009.
The program will also offer mail service prescriptions through the A&P Mail Order Pharmacy. Plan members will have the option of receiving a 90-day supply of maintenance medications at A&P and subsidiary Pharmacy Centers. The Pharmacy Centers offer one-stop shopping including health screenings, diabetic supplies and patient counseling and information service.
Within the next few weeks, 4D plans to launch group and broker marketing activities.
“This partnership brings our pharmacy offerings to the next level with dynamic services which provide our customers with the information and benefits they need to make healthy decisions in all aspects of their lives,” stated Rebecca Philbert, A&P senior vice president of merchandising, supply and logistics.
In addition, Live Better! Wellness Program pharmacists will provide on-site visits to employer groups to assist with health and prescription drug education.
Teva’s Azilect slows Parkinson’s disease in trials
WASHINGTON Results from a Phase III clinical trial have shown that Teva Pharmaceutical’s Azilect 1-mg tablets can slow the progression of the disease, the drug maker announced.
Researchers gave 1,176 Parkinson’s disease patients daily 1- to 2-mg doses of Azilect for 18 months or a placebo for the first nine months and the drug for the second nine months.
Patients who took the 1-mg dose of Azilect showed significant improvement compared with patients in the placebo group.
The Food and Drug Administration approved Azilect in May 2006 as a monotherapy for early-stage ParkinsonOs disease and as an adjunct therapy to levodopa in moderate-to-advanced stages of the disease.
The drug, known generically as rasagiline mesylate, is available in 30 countries. Danish drug maker Lundbeck markets it in Europe, and both companies plan to co-promote it in the United Kingdom, Germany and France.
Taro to ask for extension on Sun Pharmaceuticals’ offer
TEL AVIV,, Israel Taro Pharmaceutical Industries has said it will appeal to Israel’s Supreme Court to contest a ruling in the Tel Aviv District Court regarding India-based Sun Pharmaceuticals’ offer to acquire the Israeli generic drug maker.
The District Court judge had called Taro’s demand for a tender offer from Sun disingenuous, considering Taro’s acceptance of the offer a year ago.
Taro plans to ask the Supreme Court to extend the deadline for Sun’s offer, which was Tuesday at 5 p.m.